Table 1. Clinical and biologic... | American Society of Hematology

Table 1.

Clinical and biologic characteristics of 28 consecutive T-ALL patients

Characteristics	No.
Sex (female:male)	12:16
Median age, y (range)	6.6 (1-14)
WBC count, median (range)	104 × 10⁹/L (1-999 × 10⁹/L)
Hemoglobin level, median (range)	8.7 × 10⁹/L (4.5-15 × 10⁹/L)
Bulky disease^*	14 of 28
With mediastinal enlargement	8 of 28
Without mediastinal enlargement	6 of 28
Bone marrow partial involvement^†	1 of 28
Risk-adapted treatment arms
High risk	18 of 27
Very high risk^‡	9 of 27
Corticoresistant patients	11 of 27
M3 at day 21	5 of 28
Induction failure	2 of 28
2-year EFS rate	64.7%
Number of events	6 of 28
Overall survival rate	82.1%
Follow-up time, median	28 mo

Characteristics	No.
Sex (female:male)	12:16
Median age, y (range)	6.6 (1-14)
WBC count, median (range)	104 × 10⁹/L (1-999 × 10⁹/L)
Hemoglobin level, median (range)	8.7 × 10⁹/L (4.5-15 × 10⁹/L)
Bulky disease^*	14 of 28
With mediastinal enlargement	8 of 28
Without mediastinal enlargement	6 of 28
Bone marrow partial involvement^†	1 of 28
Risk-adapted treatment arms
High risk	18 of 27
Very high risk^‡	9 of 27
Corticoresistant patients	11 of 27
M3 at day 21	5 of 28
Induction failure	2 of 28
2-year EFS rate	64.7%
Number of events	6 of 28
Overall survival rate	82.1%
Follow-up time, median	28 mo

Defined by the presence of hepatomegaly or splenomegaly reaching the umbelic or lymphoadenopathy of more than 5 cm or mediastinal enlargement.

One patient (UPNT26) had 67% blasts at diagnosis.

Patient UPNT17 is a 1-year-old child treated in INFANT protocol.